| abstract |
IMP-1 was abundantly expressed in the majority of lung cancers tested. Positive immunostaining for IMP-1 is tumor size (pT classification; P = 0.0003), non-adenocarcinoma histology (P <0.0001), low histological grade (P = 0.0001) and poor prognosis (P = 0.0053) There was a correlation. Suppression of IMP-1 expression using siRNA effectively suppressed the growth of NSCLC cells. IMP-1 had the ability to bind to mRNAs encoding various proteins involved in signal transduction, cell cycle progression, cell adhesion and cytoskeleton, and various types of enzyme activities. These results suggest that IMP-1 expression may play an important role in the development and progression of lung cancer, suggesting that IMP-1 is a prognostic marker and a promising therapeutic target for lung cancer treatment. |